Cipla Soon to Launch Generic Hepatitis C Drug as Hepcvir

Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available as Hepcvir in India.

The generic drug Sofosbuvir for treating chronic Hepatitis C in India is soon to be launched under the brand name 'Hepcvir'.

"Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C which reduce the need for injectables," Cipla Chief Medical Officer Jaideep Gogtay said.

Hepatitis C - Causes, Symptoms, Diagnosis, Treatment, Complications, Prevention
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C virus.

Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available to Indian patients in a week's time.

"Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations," Cipla MD & Global CEO Subhanu Saxena said.

Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

New Treatments for Hepatitis C - Causes, Symptoms, Diagnosis
Until very recently, infection with the Hepatitis C Virus (HCV) had been very difficult to treat, but new treatments now result in curing the disease in up to 90% of cases.

Source-Medindia

Hepatitis C Drug to be Offered Soon in India at Only One Percent of Its Cost in USA
Gilead, announced voluntary licences with seven generic drug manufacturers in India to sell lower-cost versions of a $1,000-a-pill for hepatitis C treatment in poorer countries.

New Drug, Sofosbuvir, Found Very Efficient in Treating Chronic Hepatitis C Virus Infection
A new drug, Sofosbuvir, has been found very efficient in treating different types of chronic Hepatitis C Virus infection; it is in the third phase of clinical trials.